Infusions of factor VIII at 50-100 U/kg were administered "on demand" for bleeding episodes, or once weekly, in eight patients (aged 3-20 years) with hemophilia A and historically high titer inhibitors to factor VIII. Inhibitors were eliminated and immunologic tolerance to factor VIII occurred in five of the eight patients within 5-31 months. Four patients had minimal anamnestic responses upon ...

Therapeutic effectiveness of factor VIII inhibitor bypassing materials has been evaluated in dogs with hemophilia A. A standardized template gingival biopsy was performed using local anesthesia. Hemophilic dogs bled extensively from the biopsy site, whereas in normal dogs the wound was sealed within 5 + /- 2 min. If untreated, the hemophilic dogs frequently bled for several days. Factor VIII in...

background: inhibitory antibody to exogenous factor viii (fviii) is a major complication of hemophilia treatment. this study was conducted to determine the prevalence of inhibitor antibody directed against fviii.methods: from may 2010 to may 2011, 52 patients with severe hemophilia a admitted in amirkola children’s hospital were evaluated. those who had abnormal mixing study, antibody against f...

I NHIBITORS to factor VIII develop in approximately 1 5% of patients with hemophilia with an incidence of approximately 8 per 1,000 patient-years of observation.’ Clinically, these can be divided into high response inhibitors, which exhibit an anamnestic response after exposure to factor VIII, and low response inhibitors, which do not exhibit significant anamnesis.2 Because of their neutralizin...

The development of an immune response to infused factor VIII is a complication affecting many patients with hemophilia A. Inhibitor antibodies bind to antigenic determinants on the factor VIII molecule and block its procoagulant activity. A patient-derived inhibitory immunoglobulin G4kappa antibody (BO2C11) produced by an immortalized memory B-lymphocyte cell line interferes with the binding of...

The development of an immune response to infused factor VIII is a complication affecting many patients with hemophilia A. Inhibitor antibodies bind to antigenic determinants on the factor VIII molecule and block its procoagulant activity. A patient-derived inhibitory immunoglobulin G4k antibody (BO2C11) produced by an immortalized memory B-lymphocyte cell line interferes with the binding of fac...

I NHIBITORS to factor VIII develop in approximately 1 5% of patients with hemophilia with an incidence of approximately 8 per 1,000 patient-years of observation.’ Clinically, these can be divided into high response inhibitors, which exhibit an anamnestic response after exposure to factor VIII, and low response inhibitors, which do not exhibit significant anamnesis.2 Because of their neutralizin...

UNLABELLED INTRODUCTION The development of factor VIII inhibitors is a serious complication of replacement therapy in patients with congenital hemophilia A. Immune tolerance induction has been accepted as the only clinically proven treatment allowing antigen-specific tolerance to factor VIII. However, some of its issues, such as patient selection, timing, factor VIII dosing, use of immunosup...

Introduction: Hemophilia A is an inherited disease caused by a deficiency of factor VIII, which results from a genetic inheritance located on the X chromosome. During treatment of patients with this disorder, factor VIII inhibitors may be present, which are primarily antibodies type immunoglobulin G (IgG), and interfere with the activation of factor VIII. Objectives: The present study aims to i...